MoonLake Immunotherapeutics (MLTX) - Total Assets
Based on the latest financial reports, MoonLake Immunotherapeutics (MLTX) holds total assets worth $424.43 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is MoonLake Immunotherapeutics's book value for net asset value and shareholders' equity analysis.
MoonLake Immunotherapeutics - Total Assets Trend (2020–2025)
This chart illustrates how MoonLake Immunotherapeutics's total assets have evolved over time, based on quarterly financial data.
MoonLake Immunotherapeutics - Asset Composition Analysis
Current Asset Composition (December 2025)
MoonLake Immunotherapeutics's total assets of $424.43 Million consist of 99.4% current assets and 0.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 78.8% |
| Accounts Receivable | $4.87 Million | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how MoonLake Immunotherapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MoonLake Immunotherapeutics (MLTX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MoonLake Immunotherapeutics's current assets represent 99.4% of total assets in 2025, an increase from 1.4% in 2020.
- Cash Position: Cash and equivalents constituted 78.8% of total assets in 2025, up from 1.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 1.2% of total assets.
MoonLake Immunotherapeutics Competitors by Total Assets
Key competitors of MoonLake Immunotherapeutics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
MoonLake Immunotherapeutics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.27 | 21.11 | 24.33 |
| Quick Ratio | 9.27 | 21.11 | 24.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $376.22 Million | $451.82 Million | $1.40 Million |
MoonLake Immunotherapeutics - Advanced Valuation Insights
This section examines the relationship between MoonLake Immunotherapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.09 |
| Latest Market Cap to Assets Ratio | 2.83 |
| Asset Growth Rate (YoY) | -11.2% |
| Total Assets | $424.43 Million |
| Market Capitalization | $1.20 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values MoonLake Immunotherapeutics's assets at a significant premium (2.83x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: MoonLake Immunotherapeutics's assets decreased by 11.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MoonLake Immunotherapeutics (2020–2025)
The table below shows the annual total assets of MoonLake Immunotherapeutics from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $424.43 Million | -11.19% |
| 2024-12-31 | $477.93 Million | -9.23% |
| 2023-12-31 | $526.54 Million | +585.21% |
| 2022-12-31 | $76.84 Million | +693.63% |
| 2021-12-31 | $9.68 Million | -91.70% |
| 2020-12-31 | $116.63 Million | -- |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more